IMAB Share Based Compensation from 2010 to 2024

IMAB Stock  USD 1.81  0.02  1.12%   
Check I Mab financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IMAB main balance sheet or income statement drivers, such as Tax Provision of 761.5 K, Net Interest Income of 16 M or Interest Income of 19.9 M, as well as many exotic indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.69 or Book Value Per Share of 37.43. IMAB financial statements analysis is a perfect complement when working with I Mab Valuation or Volatility modules.
  
This module can also supplement I Mab's financial leverage analysis and stock options assessment as well as various I Mab Technical models . Check out the analysis of I Mab Correlation against competitors.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.

About I Mab Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include I Mab income statement, its balance sheet, and the statement of cash flows. I Mab investors use historical funamental indicators, such as I Mab's Share Based Compensation, to determine how well the company is positioned to perform in the future. Although I Mab investors may use each financial statement separately, they are all related. The changes in I Mab's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on I Mab's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on I Mab Financial Statements. Understanding these patterns can help to make the right decision on long term investment in I Mab. Please read more on our technical analysis and fundamental analysis pages.
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards I Mab in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, I Mab's short interest history, or implied volatility extrapolated from I Mab options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:
Check out the analysis of I Mab Correlation against competitors.
For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.
Note that the I Mab information on this page should be used as a complementary analysis to other I Mab's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for IMAB Stock analysis

When running I Mab's price analysis, check to measure I Mab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy I Mab is operating at the current time. Most of I Mab's value examination focuses on studying past and present price action to predict the probability of I Mab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move I Mab's price. Additionally, you may evaluate how the addition of I Mab to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Commodity Directory
Find actively traded commodities issued by global exchanges
Is I Mab's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.72)
Revenue Per Share
0.312
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.23)
Return On Equity
(0.62)
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.